Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci

Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and no...

Full description

Saved in:
Bibliographic Details
Published inPharmacy Vol. 9; no. 4; p. 175
Main Authors Wingler, Mary Joyce, Patel, Neel R., King, S. Travis, Wagner, Jamie L., Barber, Katie E., Stover, Kayla R.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 26.10.2021
MDPI
Subjects
anti-infectives
Antibiotics
Antimicrobial agents
Biofilms
Catheters
enterococcus
genitourinary
infectious diseases
Laboratories
Length of stay
linezolid
Nosocomial infections
Patient safety
Urinary tract diseases
Urinary tract infections
Urine
Urogenital system
vancomycin-resistant
United States > US
Online AccessGet full text

Cover

Abstract Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.
AbstractList Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.
Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid ( p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group ( p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.
Author Wingler, Mary Joyce
Wagner, Jamie L.
Patel, Neel R.
Stover, Kayla R.
King, S. Travis
Barber, Katie E.
AuthorAffiliation 4 Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA; jwagner@umc.edu (J.L.W.); kbarber@umc.edu (K.E.B.)
1 Department of Antimicrobial Stewardship, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA; mwingler@umc.edu
2 Department of Pharmacy, Baptist Health Care, 1000 W Morena St, Pensacola, FL 32501, USA; neelpatelpharm@gmail.com
3 Department of Pharmacy, Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA 70121, USA; samuel.king@ochsner.org
AuthorAffiliation_xml – name: 1 Department of Antimicrobial Stewardship, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA; mwingler@umc.edu
– name: 3 Department of Pharmacy, Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA 70121, USA; samuel.king@ochsner.org
– name: 4 Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA; jwagner@umc.edu (J.L.W.); kbarber@umc.edu (K.E.B.)
– name: 2 Department of Pharmacy, Baptist Health Care, 1000 W Morena St, Pensacola, FL 32501, USA; neelpatelpharm@gmail.com
Author_xml – sequence: 1
  givenname: Mary Joyce
  orcidid: 0000-0002-2037-2616
  surname: Wingler
  fullname: Wingler, Mary Joyce
– sequence: 2
  givenname: Neel R.
  surname: Patel
  fullname: Patel, Neel R.
– sequence: 3
  givenname: S. Travis
  orcidid: 0000-0002-0952-3321
  surname: King
  fullname: King, S. Travis
– sequence: 4
  givenname: Jamie L.
  orcidid: 0000-0002-6006-7894
  surname: Wagner
  fullname: Wagner, Jamie L.
– sequence: 5
  givenname: Katie E.
  orcidid: 0000-0002-8411-3111
  surname: Barber
  fullname: Barber, Katie E.
– sequence: 6
  givenname: Kayla R.
  orcidid: 0000-0002-8635-0137
  surname: Stover
  fullname: Stover, Kayla R.
BookMark eNpdkkuLFDEQgBtZcdd1z14bvHhpN4_uPC6CDKsODAgyeg3VSWUnQ3cyJj3C-OuNziLu5lKh6quPoqiXzUVMEZvmNSXvONfk9rCDPIM9adITKodnzRVjTHS9VPLiv_9lc1PKntSnKVfD8KK55L3qmdT0qhk3IeKvNAXX-pTbZYftNiMsM8alTb79lkOEfKpJsEu7jh7tElIs7QqOBV07ntrvEG2aTzbE7iuWUBaorXdxwZxssja8ap57mArePMTrZvvxbrv63G2-fFqvPmw6y3W_dCid1mSUwBxzaqBy7L0H9Np5q5gDYrn3zI2a04Gj5Nrr0YEYOadS2J5fN-uz1iXYm0MOc53bJAjmbyLlewN5CXZCY4V3wnNUjkDvgQHj1aApcnCaDay63p9dh-M4o7N1GRmmR9LHlRh25j79NEowpRSpgrcPgpx-HLEsZg7F4jRBxHQshgnS90JySiv65gm6T8cc66YqRZliRAhRqdszZXMqJaP_Nwwl5s81mCfXwH8DzWqsRQ
CitedBy_id crossref_primary_10_1111_tid_13924
crossref_primary_10_1007_s12223_022_01002_2
crossref_primary_10_1080_17512433_2022_2121703
crossref_primary_10_1007_s40121_023_00826_w
crossref_primary_10_1016_j_cmi_2022_05_016
crossref_primary_10_3390_antibiotics11070857
Cites_doi 10.1128/AAC.47.12.3789-3794.2003
10.1016/j.jbi.2008.08.010
10.1086/591861
10.1093/ofid/ofw172.259
10.1093/ofid/ofu052.753
10.2147/IDR.S54125
10.4111/icu.2016.57.2.129
10.1128/AAC.00455-10
10.1016/j.diagmicrobio.2006.12.022
10.52547/rbmb.10.1.50
10.1586/14787210.2.1.51
10.1177/2050312120970743
10.1128/AAC.01817-15
10.1016/j.ijantimicag.2017.06.008
10.3389/fpubh.2021.570650
10.1592/phco.30.11.1136
10.1097/IPC.0000000000000193
10.1093/cid/ciq257
10.1177/1060028018783498
10.1038/s41598-020-74834-y
10.1086/668770
10.2147/IDR.S311229
10.4065/81.4.529
10.1017/ice.2016.174
10.3390/children8070585
10.1345/aph.1R604
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/pharmacy9040175
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
ProQuest Central Student
Research Library Prep
Research Library (ProQuest)
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2226-4787
ExternalDocumentID oai_doaj_org_article_c6fd6f3e8d0a4fa2a236c491e3ad9252
10_3390_pharmacy9040175
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID 3V.
53G
5VS
8G5
AADQD
AAYXX
ABUWG
ADBBV
ADFRT
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BCNDV
BENPR
BPHCQ
CCPQU
CITATION
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HYE
IAO
KQ8
M2O
MK0
MODMG
M~E
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
7XB
8FK
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c394t-e7d990b7a2d2d8517b4ffaef9dfc82da0c3ff2db93153e739f9bda6b33176c43
IEDL.DBID RPM
ISSN 2226-4787
IngestDate Fri Oct 04 13:11:31 EDT 2024
Tue Sep 17 21:12:18 EDT 2024
Fri Aug 16 23:27:44 EDT 2024
Thu Oct 10 15:47:41 EDT 2024
Fri Aug 23 05:12:08 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c394t-e7d990b7a2d2d8517b4ffaef9dfc82da0c3ff2db93153e739f9bda6b33176c43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Work completed while Patel was a student at the University of Mississippi School of Pharmacy.
ORCID 0000-0002-6006-7894
0000-0002-8411-3111
0000-0002-2037-2616
0000-0002-8635-0137
0000-0002-0952-3321
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628880/
PMID 34842791
PQID 2612820666
PQPubID 2032348
ParticipantIDs doaj_primary_oai_doaj_org_article_c6fd6f3e8d0a4fa2a236c491e3ad9252
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8628880
proquest_miscellaneous_2604467311
proquest_journals_2612820666
crossref_primary_10_3390_pharmacy9040175
PublicationCentury 2000
PublicationDate 20211026
PublicationDateYYYYMMDD 2021-10-26
PublicationDate_xml – month: 10
  year: 2021
  text: 20211026
  day: 26
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Pharmacy
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Pontefract (ref_19) 2020; 8
Taimur (ref_23) 2015; 23
(ref_4) 2020; 10
Shah (ref_24) 2018; 51
Campbell (ref_27) 2016; 1
Heintz (ref_12) 2010; 30
Hidron (ref_2) 2008; 29
Moenster (ref_16) 2014; 1
Cole (ref_25) 2015; 59
Rabon (ref_21) 2018; 52
Sievert (ref_3) 2013; 34
Deshpande (ref_22) 2007; 58
Tajbakhsh (ref_8) 2021; 10
Wagenlehner (ref_15) 2003; 47
Toner (ref_13) 2016; 57
Vidaillac (ref_9) 2010; 54
Ramsey (ref_20) 2013; 47
Ma (ref_5) 2021; 9
Crank (ref_10) 2015; 8
ref_26
Stevens (ref_14) 2004; 2
Kuwa (ref_7) 2021; 14
Zirakzadeh (ref_11) 2006; 81
Weiner (ref_1) 2016; 37
ref_6
Gupta (ref_17) 2011; 52
Harris (ref_18) 2009; 42
References_xml – volume: 47
  start-page: 3789
  year: 2003
  ident: ref_15
  article-title: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.47.12.3789-3794.2003
  contributor:
    fullname: Wagenlehner
– volume: 42
  start-page: 377
  year: 2009
  ident: ref_18
  article-title: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
  publication-title: J. Biomed. Inform.
  doi: 10.1016/j.jbi.2008.08.010
  contributor:
    fullname: Harris
– volume: 29
  start-page: 996
  year: 2008
  ident: ref_2
  article-title: NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007
  publication-title: Infect. Control Hosp. Epidemiol.
  doi: 10.1086/591861
  contributor:
    fullname: Hidron
– volume: 1
  start-page: 395
  year: 2016
  ident: ref_27
  article-title: Urine culture stewardship as a component of urinary catheter infection prevention in five intensive care units
  publication-title: Open Forum Infect. Dis.
  doi: 10.1093/ofid/ofw172.259
  contributor:
    fullname: Campbell
– ident: ref_26
– volume: 1
  start-page: S306
  year: 2014
  ident: ref_16
  article-title: Linezolid compared to daptomycin for the treatment of vancomycin-resistant enterococcal urinary tract infections
  publication-title: Open Form Infect. Dis.
  doi: 10.1093/ofid/ofu052.753
  contributor:
    fullname: Moenster
– volume: 8
  start-page: 217
  year: 2015
  ident: ref_10
  article-title: Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management
  publication-title: Infect. Drug Resist.
  doi: 10.2147/IDR.S54125
  contributor:
    fullname: Crank
– volume: 57
  start-page: 129
  year: 2016
  ident: ref_13
  article-title: Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom
  publication-title: Investig. Clin. Urol.
  doi: 10.4111/icu.2016.57.2.129
  contributor:
    fullname: Toner
– volume: 54
  start-page: 4329
  year: 2010
  ident: ref_9
  article-title: Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00455-10
  contributor:
    fullname: Vidaillac
– volume: 58
  start-page: 163
  year: 2007
  ident: ref_22
  article-title: Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2006.12.022
  contributor:
    fullname: Deshpande
– volume: 10
  start-page: 50
  year: 2021
  ident: ref_8
  article-title: Prevalence of virulence genes and antibiotic resistance pattern in Enterococcus faecalis isolated from urinary tract infection in Shahrekord, Iran
  publication-title: Rep. Biochem. Mol. Biol.
  doi: 10.52547/rbmb.10.1.50
  contributor:
    fullname: Tajbakhsh
– volume: 2
  start-page: 51
  year: 2004
  ident: ref_14
  article-title: A review of linezolid: The first oxazolidinone antibiotic
  publication-title: Expert Rev. Anti-Infect. Ther.
  doi: 10.1586/14787210.2.1.51
  contributor:
    fullname: Stevens
– volume: 8
  start-page: 2050312120970743
  year: 2020
  ident: ref_19
  article-title: Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus
  publication-title: SAGE Open Med.
  doi: 10.1177/2050312120970743
  contributor:
    fullname: Pontefract
– volume: 59
  start-page: 7362
  year: 2015
  ident: ref_25
  article-title: Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01817-15
  contributor:
    fullname: Cole
– volume: 51
  start-page: 57
  year: 2018
  ident: ref_24
  article-title: Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): A single-center university hospital experience
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2017.06.008
  contributor:
    fullname: Shah
– volume: 9
  start-page: 570650
  year: 2021
  ident: ref_5
  article-title: Linezolid resistance in Enterococcus faecalis associated with urinary tract infections of patients in a tertiary hospitals in China: Resistance mechanisms, virulence, and risk factors
  publication-title: Front. Public Health
  doi: 10.3389/fpubh.2021.570650
  contributor:
    fullname: Ma
– volume: 30
  start-page: 1136
  year: 2010
  ident: ref_12
  article-title: Vancomycin-resistant enterococcal urinary tract infections
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.30.11.1136
  contributor:
    fullname: Heintz
– volume: 23
  start-page: 72
  year: 2015
  ident: ref_23
  article-title: Empiric and targeted treatment of enterococcal infections: Opportunities for antimicrobial stewardship
  publication-title: Infect. Dis. Clin. Pract.
  doi: 10.1097/IPC.0000000000000193
  contributor:
    fullname: Taimur
– volume: 52
  start-page: e103
  year: 2011
  ident: ref_17
  article-title: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciq257
  contributor:
    fullname: Gupta
– volume: 52
  start-page: 1162
  year: 2018
  ident: ref_21
  article-title: Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater
  publication-title: Ann. Pharmacother.
  doi: 10.1177/1060028018783498
  contributor:
    fullname: Rabon
– volume: 10
  start-page: 17658
  year: 2020
  ident: ref_4
  article-title: Increasing relevance of Gram-positive cocci in urinary tract infections: A 10-year analysis of their prevalence and resistance trends
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-74834-y
– volume: 34
  start-page: 1
  year: 2013
  ident: ref_3
  article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010
  publication-title: Infect. Control Hosp. Epidemiol.
  doi: 10.1086/668770
  contributor:
    fullname: Sievert
– volume: 14
  start-page: 2883
  year: 2021
  ident: ref_7
  article-title: Catheter-associated urinary tract infection: Incidence, associated factors and drug resistance patterns of bacterial isolates in southern Ethiopia
  publication-title: Infect. Drug Resist.
  doi: 10.2147/IDR.S311229
  contributor:
    fullname: Kuwa
– volume: 81
  start-page: 529
  year: 2006
  ident: ref_11
  article-title: Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment
  publication-title: Mayo Clin. Proc.
  doi: 10.4065/81.4.529
  contributor:
    fullname: Zirakzadeh
– volume: 37
  start-page: 1288
  year: 2016
  ident: ref_1
  article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014
  publication-title: Infect. Control Hosp. Epidemiol.
  doi: 10.1017/ice.2016.174
  contributor:
    fullname: Weiner
– ident: ref_6
  doi: 10.3390/children8070585
– volume: 47
  start-page: 543
  year: 2013
  ident: ref_20
  article-title: Serotonergic and adrenergic drug interactions associated with linezolid: A critical review and practical management approach
  publication-title: Ann. Pharmacother.
  doi: 10.1345/aph.1R604
  contributor:
    fullname: Ramsey
SSID ssj0000913855
Score 2.2717097
Snippet Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 175
SubjectTerms anti-infectives
Antibiotics
Antimicrobial agents
Biofilms
Catheters
enterococcus
genitourinary
infectious diseases
Laboratories
Length of stay
linezolid
Nosocomial infections
Patient safety
Urinary tract diseases
Urinary tract infections
Urine
Urogenital system
vancomycin-resistant
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTr1UlIcILJWRKsRhIxK_Eh8LKqJIrVC1VNwiP8VKJVltdg_Lr2fsZJdNL1x6jR3FmRnPfCOPv0Hoq1O5V46L1DhJU6YKmaqSszTnxgS-OsljF4Wfv8TtA7t75I9brb5CTVhHD9wJ7tIIb4WnrrSZYl4RRagwTOaOKisJ77xvzreSqeiDZU5LzjsuHwp5_eWsY4JeSbDaPFQVboWhyNY_gJjDAsmtiHOziz71UBF_65b4GX1w9R46v--_MMaTt6tT7Rif4_s3FurVPtKQZbqX5u_UYsClGHAenqyLynHj8cM83sSFh8os8I--Jqtu8bVats5ivcJ_wCKa55WZ1ulv1wagCa_GKoIG3KiZHqDJzffJ9W3aN1RIDZVskbrCQvDRhSKWWIBahWYeNOWl9aYkVmWGek-slhT8oCuo9FJbJTQFkAFCp4dop25qd4RwljmujaWgS8gQmYekSWdEZSJzzIKXSNDFWrzVrKPNqCDdCJqo_tFEgq6C-DfTAt91fABWUPVWUL1nBQkarZVX9ZuwrQI7WqSrFwk62wzD9glnIqp2zTLMCSfaBc3zBBUDpQ8WNBypp0-RiLsMvZrL7Ph__MEJ-khCuQyERSJGaGcxX7pTwDsL_SWa9isSGARw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELZauPRSQR9qCq2MVKEesEj8SnyqAIGgUtEKLRW3yM-yUptsN7uH7a_vOOvdJT30aiey5RmPv_GMv0Hok9dF0F5IYr1ihOtSEV0JTgphbeSrU6KvovDtVl7f868P4iFduHUprXJtE3tD7Vob78hPI9VVzz0uv0x_k1g1KkZXUwmN52iXFjyGaXfPL29Hd5tblsh6WQmx4vRh4N-fTleM0EsF2lvE7MInx1HP2j-AmsNEyScnz9UeepkgIz5byXgfPfPNK3Q8SiOc4PH2CVV3go_xaMtGvXyNDHib_k_7c-Iw4FMMeA-P18nluA34fta_yIVGbef4JuVmNR2-0IvOO2yW-DtoRvtraScNufNdBJzwa59N0II5tZM3aHx1Ob64JqmwArFM8TnxpYNDyJSaOuoAcpWGB5BYUC7YijqdWxYCdUYxsIe-ZCoo47Q0DMCGtJy9RTtN2_h3COe5F8Y6BjIFT5EHcJ5MTnUuc88dWIsMfV4vbz1d0WfU4HZESdT_SCJD53H5N59F3uu-oZ39qNM2qq0MTgbmK5drHjTVlMGEVOGZdooKmqHDtfDqtBm7eqs6GTradMM2irER3fh2Eb-Jke2SFUWGyoHQBxMa9jSTx56Qu4o1m6v8_f8HP0AvaEyIgYOPykO0M58t_AdANHPzMantX9tx_G8
  priority: 102
  providerName: ProQuest
Title Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
URI https://www.proquest.com/docview/2612820666
https://search.proquest.com/docview/2604467311
https://pubmed.ncbi.nlm.nih.gov/PMC8628880
https://doaj.org/article/c6fd6f3e8d0a4fa2a236c491e3ad9252
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB6MvY1fmtQsajLKHurF1sa3HNbR0g5ZQ0tE3o-tmaOwQJw_pr9-RYrfxHveqCxY6RzrfsT59QuirlamTlmextoLGTOYilgVnccq19np1godXFK5vsqs79vOe3-8h3t-FCaR9raqz-mF-Vld_ArdyMdfjnic2nl5PCv9GbpGM99F-TulOih62X5HSgvOtjA-FlH682IpAbwQ4LETLQ_SSsoKRoMu5E4yCZv8AaA5pkjtx5_I1etUBRvx9O7A3aM_Wb9HJtPvYKZ49X6BqT_EJnj5rUW_eIQW5pn1sHiqDAZ1iQHt41lPLcePw3TLcx4VCqVf4R8fMqls8kevWGqw2-Bf4RTPf6KqOb23r4SZ0DVyCBjZTXb1Hs8uL2eQq7p5ViDUVbBXb3EAIUrkkhhgAXLliDuzlhHG6IEYmmjpHjBIUdkObU-GEMjJTFKBGphn9gA7qprYfEU4Sy5U2FCwKeSJzkDqphMgkSywzsFdE6Fs_veViK55RQtLhjVL-Y5QInfvpf2rmVa9DQbP8XXa2L3XmTOaoLUwimZNEEgoDEqml0gjCSYSOe-OV3VJsS6-RFkTrswh9eaqGReRPRmRtm7Vv48-1c5qmEcoHRh8MaFgD3hnkuDtv_PTfPY_QIfFMGYiIJDtGB6vl2n4GqLNSI_Ti_OJmejsKvwpGwdH_Ak_6Br4
link.rule.ids 230,315,733,786,790,870,891,2115,21416,27955,27956,33777,33778,43838,53825,53827,74657
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDCa29LBdij0xd92mAUOxQ43akl86FWvRIt3aICjcoTdDzy1Aa2dxcsh-fSlHSeoddpVsSBAp8qNEfQT4YkRshUmzUBnOwkTkPBRFmoRxqpTjq-NpV0XhapQNb5Lvt-mtP3BrfVrl2iZ2hlo3yp2RHzmqq457PDue_gld1Sh3u-pLaDyFHUe5WQxg5-RsNL7enLI41ssiTVecPgzj-6PpihF6yVF7Y5dd-Mgddaz9PajZT5R85HnOX8Cuh4zk20rGL-GJqV_BwdiPcEjK7ROq9pAckPGWjXr5GiRGm-ZvczfRBPEpQbxHynVyOWksuZl1L3KxUag5ufC5WXVLTsWiNZrIJfmJmtHcL9WkDq9N6wAn_tplEzRoTtXkDZTnZ-XpMPSFFULFeDIPTa7RCclcUE01Qq5cJhYlZrm2qqBaRIpZS7XkDO2hyRm3XGqRSYZgI1MJewuDuqnNOyBRZFKpNEOZYqSYWAyeZERFlEUm0WgtAvi6Xt5quqLPqDDscJKo_pFEACdu-TefOd7rrqGZ_ar8NqpUZnVmmSl0JBIrqKAMJ8Rjw4TmNKUB7K-FV_nN2FZb1Qng86Ybt5G7GxG1aRbuG3eznbM4DiDvCb03oX5PPfndEXIXrmZzEe39f_BP8GxYXl1WlxejH-_hOXXJMegEabYPg_lsYT4gupnLj16FHwDyY_9l
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgkxAviKsIG2AkNPGwqIlviZ8QG6s2LlU1dWhvka-jEktK0z6UX89x6rYLD7zaiWz5HJ-L_fk7CL13KvfKcZEaJ2nKVCFTVXKW5tyYwFcneVdF4ftInF-xL9f8OuKf2gir3NjEzlDbxoQz8kGguuq4x8XAR1jE-PPw4-x3GipIhZvWWE7jPtovmOCQiO2fnI3Gl9sTl8CAWXK-5vehkOsPZmt26JUETc4D0vCOa-oY_HthZx80eccLDR-jRzF8xJ_W8n6C7rn6KToaxxGO8WT3nKo9xkd4vGOmXj1DGjJP96f5NbUYYlUMsR-ebIDmuPH4at69zoVGZRb4IuK06hafqmXrLNYr_AO0pLldmWmdXro2BJ_wa4csaMC0mulzNBmeTU7P01hkITVUskXqCgsOSReKWGIh_Co08yA9L603JbEqM9R7YrWkYBtdQaWX2iqhKQQewjD6Au3VTe1eIpxljmtjKcgXskbmIZHSGVGZyByzYDkS9GGzvNVsTaVRQQoSJFH9I4kEnYTl334WOLC7hmZ-U8UtVRnhrfDUlTZTzCuiCIUJydxRZSXhJEGHG-FVcWO21U6NEvRu2w1bKtyTqNo1y_BNuOUuaJ4nqOgJvTehfk89_dmRc5ehfnOZvfr_4G_RA9De6tvF6OsBekgCTgb8IRGHaG8xX7rXEOgs9JuowX8BidcDqA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Linezolid+for+the+Treatment+of+Urinary+Tract+Infections+Caused+by+Vancomycin-Resistant+Enterococci&rft.jtitle=Pharmacy&rft.au=Wingler%2C+Mary+Joyce&rft.au=Patel%2C+Neel+R&rft.au=King%2C+S+Travis&rft.au=Wagner%2C+Jamie+L&rft.date=2021-10-26&rft.eissn=2226-4787&rft.volume=9&rft.issue=4&rft_id=info:doi/10.3390%2Fpharmacy9040175&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2226-4787&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2226-4787&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2226-4787&client=summon